Share Price and Basic Stock Data
Last Updated: December 6, 2025, 9:46 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Panacea Biotec Ltd operates in the pharmaceuticals industry, focusing on vaccines and biopharmaceuticals. The company’s recent revenue trajectory has shown signs of volatility, with sales reported at ₹460 Cr for FY 2023, a significant drop from ₹661 Cr in the previous fiscal year. However, the trailing twelve months (TTM) figure indicates a recovery, rising to ₹610 Cr, suggesting a potential rebound. The quarterly sales reflect this trend, notably with a peak of ₹150.50 Cr recorded in December 2023, though subsequent quarters exhibit fluctuations, such as a dip to ₹115.72 Cr in June 2024. Such inconsistent performance may concern investors, especially when viewed against the backdrop of a broader industry that typically enjoys more stable growth patterns. The company’s ability to stabilize and grow its revenue will be crucial for regaining investor confidence.
Profitability and Efficiency Metrics
Profitability remains a significant challenge for Panacea Biotec, as evidenced by its negative operating profit margins (OPM). The OPM stood at -0.71%, indicating that the company is currently struggling to manage its costs effectively. Historical data shows that operating profits have been in the red for several quarters, with the most recent figures reflecting a loss of ₹26.88 Cr in March 2025. The net profit also paints a bleak picture, with a loss of ₹9 Cr for the same period. Efficiency metrics like Return on Equity (ROE) at 4.92% and Return on Capital Employed (ROCE) at 4.57% are low, suggesting that the company’s capital is not being utilized effectively. A high cash conversion cycle of 25 days indicates that the company is taking longer to convert its investments into cash flow, adding further pressure to its liquidity position.
Balance Sheet Strength and Financial Ratios
Panacea Biotec’s balance sheet reveals a mix of strengths and weaknesses. The company reported reserves of ₹820 Cr, which provides a cushion for potential operational challenges. However, with borrowings standing at only ₹23 Cr, the leverage appears low, which could limit growth opportunities if the company seeks to expand. The Interest Coverage Ratio (ICR) at -1.35x is concerning, suggesting that the company is currently unable to cover its interest obligations from its earnings, which raises questions about its financial health. The Price-to-Book Value (P/BV) ratio at 3.24x indicates that the stock may be trading at a premium compared to its book value, which can be a red flag for value-oriented investors. Overall, while the balance sheet appears to have a solid reserve base, the profitability and efficiency metrics suggest that the company needs to address significant operational challenges to improve its financial standing.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Panacea Biotec indicates a strong promoter holding of 72.48%, which can instill confidence among retail investors. This level of promoter commitment often suggests a long-term vision for the company. However, foreign institutional investors (FIIs) and domestic institutional investors (DIIs) hold relatively modest stakes of 1.06% and 1.80%, respectively, indicating limited institutional interest. The public shareholding stands at 24.65%, with a total of 33,593 shareholders. The gradual decline in public shareholding from 25.81% in December 2022 to the current levels may raise concerns about retail investor confidence. If the company can demonstrate a turnaround in profitability and operational efficiency, it may attract greater institutional interest, which could stabilize the stock price and enhance investor sentiment.
Outlook, Risks, and Final Insight
The outlook for Panacea Biotec appears precarious, given the current financial metrics. While there are indicators of potential recovery in revenue, the persistent issues around profitability and operational efficiency cannot be overlooked. The risks include ongoing volatility in revenue, insufficient cash flows to cover operational costs, and a low interest coverage ratio that could threaten financial stability. Additionally, the pharmaceutical sector is competitive, and any delays in product development or regulatory approvals could further impact the company’s performance. For investors, the key will be to monitor the company’s ability to navigate these challenges and implement a robust strategy for growth. As the company works towards regaining its footing, prudent investors should weigh the potential for recovery against the significant operational hurdles that lie ahead.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Panacea Biotec Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 146 Cr. | 116 | 247/84.3 | 32.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,112 Cr. | 377 | 479/192 | 85.2 | 24.3 | 0.18 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.5 Cr. | 47.9 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 44.0 Cr. | 30.0 | 30.5/17.0 | 105 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,580.44 Cr | 1,173.08 | 51.95 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 110.70 | 105.12 | 115.20 | 128.93 | 129.19 | 143.02 | 150.50 | 136.46 | 115.72 | 147.35 | 163.49 | 132.53 | 166.70 |
| Expenses | 190.51 | 108.96 | 123.84 | 134.60 | 139.50 | 146.58 | 150.65 | 142.50 | 129.71 | 140.35 | 155.53 | 159.41 | 167.88 |
| Operating Profit | -79.81 | -3.84 | -8.64 | -5.67 | -10.31 | -3.56 | -0.15 | -6.04 | -13.99 | 7.00 | 7.96 | -26.88 | -1.18 |
| OPM % | -72.10% | -3.65% | -7.50% | -4.40% | -7.98% | -2.49% | -0.10% | -4.43% | -12.09% | 4.75% | 4.87% | -20.28% | -0.71% |
| Other Income | 39.95 | 38.22 | 41.71 | 34.44 | 33.82 | 6.00 | 8.46 | 13.55 | 6.54 | 7.42 | 6.39 | 36.30 | 16.99 |
| Interest | 1.25 | 1.18 | 0.96 | 1.05 | 1.00 | 0.91 | 0.85 | 0.82 | 0.87 | 0.98 | 0.99 | 1.04 | 0.86 |
| Depreciation | 10.05 | 9.89 | 9.67 | 9.51 | 9.48 | 9.31 | 9.11 | 8.81 | 8.73 | 8.68 | 8.98 | 8.42 | 8.39 |
| Profit before tax | -51.16 | 23.31 | 22.44 | 18.21 | 13.03 | -7.78 | -1.65 | -2.12 | -17.05 | 4.76 | 4.38 | -0.04 | 6.56 |
| Tax % | 9.73% | 32.65% | 13.68% | 169.63% | 15.73% | 6.56% | 33.33% | -6.13% | -6.86% | 1.05% | -1.37% | 4,875.00% | 39.63% |
| Net Profit | -56.14 | 15.70 | 19.37 | -12.68 | 10.98 | -8.29 | -2.20 | -1.99 | -15.88 | 4.71 | 4.44 | -1.99 | 3.96 |
| EPS in Rs | -9.16 | 2.56 | 3.16 | -2.07 | 1.79 | -1.35 | -0.37 | -0.32 | -2.58 | 0.78 | 0.74 | -0.31 | 0.66 |
Last Updated: August 20, 2025, 5:45 am
Below is a detailed analysis of the quarterly data for Panacea Biotec Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 166.70 Cr.. The value appears strong and on an upward trend. It has increased from 132.53 Cr. (Mar 2025) to 166.70 Cr., marking an increase of 34.17 Cr..
- For Expenses, as of Jun 2025, the value is 167.88 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 159.41 Cr. (Mar 2025) to 167.88 Cr., marking an increase of 8.47 Cr..
- For Operating Profit, as of Jun 2025, the value is -1.18 Cr.. The value appears strong and on an upward trend. It has increased from -26.88 Cr. (Mar 2025) to -1.18 Cr., marking an increase of 25.70 Cr..
- For OPM %, as of Jun 2025, the value is -0.71%. The value appears strong and on an upward trend. It has increased from -20.28% (Mar 2025) to -0.71%, marking an increase of 19.57%.
- For Other Income, as of Jun 2025, the value is 16.99 Cr.. The value appears to be declining and may need further review. It has decreased from 36.30 Cr. (Mar 2025) to 16.99 Cr., marking a decrease of 19.31 Cr..
- For Interest, as of Jun 2025, the value is 0.86 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.04 Cr. (Mar 2025) to 0.86 Cr., marking a decrease of 0.18 Cr..
- For Depreciation, as of Jun 2025, the value is 8.39 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 8.42 Cr. (Mar 2025) to 8.39 Cr., marking a decrease of 0.03 Cr..
- For Profit before tax, as of Jun 2025, the value is 6.56 Cr.. The value appears strong and on an upward trend. It has increased from -0.04 Cr. (Mar 2025) to 6.56 Cr., marking an increase of 6.60 Cr..
- For Tax %, as of Jun 2025, the value is 39.63%. The value appears to be improving (decreasing) as expected. It has decreased from 4,875.00% (Mar 2025) to 39.63%, marking a decrease of 4,835.37%.
- For Net Profit, as of Jun 2025, the value is 3.96 Cr.. The value appears strong and on an upward trend. It has increased from -1.99 Cr. (Mar 2025) to 3.96 Cr., marking an increase of 5.95 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.66. The value appears strong and on an upward trend. It has increased from -0.31 (Mar 2025) to 0.66, marking an increase of 0.97.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:42 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 510 | 687 | 653 | 544 | 593 | 457 | 544 | 625 | 661 | 460 | 559 | 559 | 610 |
| Expenses | 582 | 643 | 541 | 505 | 509 | 591 | 490 | 548 | 674 | 558 | 574 | 584 | 623 |
| Operating Profit | -72 | 44 | 112 | 39 | 84 | -134 | 54 | 77 | -13 | -98 | -15 | -25 | -13 |
| OPM % | -14% | 6% | 17% | 7% | 14% | -29% | 10% | 12% | -2% | -21% | -3% | -4% | -2% |
| Other Income | 183 | 28 | 70 | 62 | 8 | 338 | -14 | 9 | 1,687 | 154 | 57 | 55 | 67 |
| Interest | 150 | 105 | 127 | 101 | 101 | 105 | 174 | 185 | 181 | 4 | 4 | 4 | 4 |
| Depreciation | 71 | 67 | 73 | 68 | 57 | 54 | 43 | 46 | 44 | 39 | 37 | 35 | 34 |
| Profit before tax | -111 | -99 | -19 | -67 | -66 | 45 | -178 | -146 | 1,449 | 13 | 1 | -8 | 16 |
| Tax % | 2% | 3% | 10% | -16% | 15% | 17% | 9% | 1% | 26% | 363% | 201% | 10% | |
| Net Profit | -113 | -108 | -21 | -56 | -76 | 38 | -194 | -148 | 1,078 | -34 | -2 | -9 | 11 |
| EPS in Rs | -18.29 | -17.38 | -2.98 | -8.89 | -12.07 | 6.15 | -31.69 | -24.09 | 175.91 | -5.42 | -0.19 | -1.37 | 1.87 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 4.42% | 80.56% | -166.67% | -35.71% | 150.00% | -610.53% | 23.71% | 828.38% | -103.15% | 94.12% | -350.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 76.13% | -247.22% | 130.95% | 185.71% | -760.53% | 634.24% | 804.67% | -931.53% | 197.27% | -444.12% |
Panacea Biotec Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | 1% |
| 3 Years: | -5% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 12% |
| 3 Years: | 21% |
| TTM: | 29% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 19% |
| 3 Years: | 43% |
| 1 Year: | 71% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -6% |
| Last Year: | -5% |
Last Updated: September 5, 2025, 12:05 pm
Balance Sheet
Last Updated: December 4, 2025, 1:46 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves | 507 | 449 | 426 | 350 | 303 | 344 | 193 | -235 | 871 | 837 | 836 | 829 | 820 |
| Borrowings | 1,060 | 1,111 | 1,105 | 994 | 941 | 646 | 742 | 820 | 34 | 20 | 21 | 22 | 23 |
| Other Liabilities | 371 | 364 | 317 | 440 | 349 | 379 | 449 | 587 | 848 | 407 | 378 | 433 | 405 |
| Total Liabilities | 1,943 | 1,930 | 1,854 | 1,789 | 1,598 | 1,376 | 1,390 | 1,178 | 1,759 | 1,271 | 1,241 | 1,290 | 1,254 |
| Fixed Assets | 1,276 | 1,144 | 1,071 | 1,001 | 949 | 806 | 657 | 609 | 622 | 600 | 582 | 567 | 594 |
| CWIP | 172 | 155 | 161 | 30 | 40 | 23 | 24 | 34 | 17 | 42 | 102 | 128 | 110 |
| Investments | 16 | 15 | 9 | 7 | 7 | 5 | 6 | 0 | 5 | 13 | 40 | 3 | 3 |
| Other Assets | 479 | 616 | 614 | 750 | 602 | 542 | 703 | 534 | 1,114 | 615 | 517 | 592 | 547 |
| Total Assets | 1,943 | 1,930 | 1,854 | 1,789 | 1,598 | 1,376 | 1,390 | 1,178 | 1,759 | 1,271 | 1,241 | 1,290 | 1,254 |
Below is a detailed analysis of the balance sheet data for Panacea Biotec Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 6.00 Cr..
- For Reserves, as of Sep 2025, the value is 820.00 Cr.. The value appears to be declining and may need further review. It has decreased from 829.00 Cr. (Mar 2025) to 820.00 Cr., marking a decrease of 9.00 Cr..
- For Borrowings, as of Sep 2025, the value is 23.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 22.00 Cr. (Mar 2025) to 23.00 Cr., marking an increase of 1.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 405.00 Cr.. The value appears to be improving (decreasing). It has decreased from 433.00 Cr. (Mar 2025) to 405.00 Cr., marking a decrease of 28.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,254.00 Cr.. The value appears to be improving (decreasing). It has decreased from 1,290.00 Cr. (Mar 2025) to 1,254.00 Cr., marking a decrease of 36.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 594.00 Cr.. The value appears strong and on an upward trend. It has increased from 567.00 Cr. (Mar 2025) to 594.00 Cr., marking an increase of 27.00 Cr..
- For CWIP, as of Sep 2025, the value is 110.00 Cr.. The value appears to be declining and may need further review. It has decreased from 128.00 Cr. (Mar 2025) to 110.00 Cr., marking a decrease of 18.00 Cr..
- For Investments, as of Sep 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
- For Other Assets, as of Sep 2025, the value is 547.00 Cr.. The value appears to be declining and may need further review. It has decreased from 592.00 Cr. (Mar 2025) to 547.00 Cr., marking a decrease of 45.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,254.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,290.00 Cr. (Mar 2025) to 1,254.00 Cr., marking a decrease of 36.00 Cr..
Notably, the Reserves (820.00 Cr.) exceed the Borrowings (23.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -73.00 | 43.00 | 111.00 | -955.00 | -857.00 | -780.00 | -688.00 | -743.00 | -47.00 | -118.00 | -36.00 | -47.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 68 | 52 | 79 | 95 | 84 | 71 | 46 | 49 | 45 | 48 | 37 | 47 |
| Inventory Days | 375 | 404 | 516 | 770 | 651 | 173 | 344 | 311 | 296 | 292 | 282 | 391 |
| Days Payable | 430 | 272 | 318 | 607 | 540 | 572 | 463 | 440 | 327 | 256 | 244 | 413 |
| Cash Conversion Cycle | 13 | 184 | 278 | 259 | 195 | -328 | -73 | -80 | 14 | 83 | 76 | 25 |
| Working Capital Days | -343 | -126 | 27 | -46 | -96 | -363 | 95 | -43 | -229 | -5 | -2 | 46 |
| ROCE % | -8% | 0% | 4% | 2% | 3% | -16% | 4% | 5% | -6% | -10% | -4% | -5% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF | 117 | 0.02 | 0 | 117 | 2025-04-22 17:25:23 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | -1.37 | -0.19 | -5.43 | 175.98 | -24.11 |
| Diluted EPS (Rs.) | -1.37 | -0.19 | -5.43 | 175.98 | -24.11 |
| Cash EPS (Rs.) | 4.26 | 5.75 | 0.87 | 183.11 | -16.68 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 136.18 | 133.94 | 133.63 | 138.09 | -41.36 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 136.18 | 133.94 | 133.63 | 138.09 | -41.36 |
| Revenue From Operations / Share (Rs.) | 91.21 | 91.29 | 75.09 | 107.96 | 102.01 |
| PBDIT / Share (Rs.) | -0.85 | 0.93 | -7.56 | -0.47 | 14.14 |
| PBIT / Share (Rs.) | -6.54 | -5.06 | -13.95 | -7.60 | 6.70 |
| PBT / Share (Rs.) | -1.30 | 0.24 | 2.09 | 236.54 | -23.56 |
| Net Profit / Share (Rs.) | -1.42 | -0.24 | -5.51 | 175.98 | -24.12 |
| NP After MI And SOA / Share (Rs.) | -1.37 | -0.19 | -5.43 | 175.98 | -24.11 |
| PBDIT Margin (%) | -0.93 | 1.02 | -10.06 | -0.43 | 13.86 |
| PBIT Margin (%) | -7.16 | -5.53 | -18.57 | -7.04 | 6.56 |
| PBT Margin (%) | -1.42 | 0.26 | 2.78 | 219.10 | -23.09 |
| Net Profit Margin (%) | -1.55 | -0.26 | -7.33 | 163.01 | -23.64 |
| NP After MI And SOA Margin (%) | -1.49 | -0.20 | -7.22 | 163.01 | -23.63 |
| Return on Networth / Equity (%) | -1.00 | -0.14 | -4.04 | 126.99 | 0.00 |
| Return on Capital Employeed (%) | -4.34 | -3.32 | -9.09 | -4.75 | 5.44 |
| Return On Assets (%) | -0.64 | -0.09 | -2.61 | 60.47 | -12.52 |
| Long Term Debt / Equity (X) | 0.02 | 0.01 | 0.01 | 0.03 | -2.92 |
| Total Debt / Equity (X) | 0.02 | 0.01 | 0.01 | 0.03 | -2.92 |
| Asset Turnover Ratio (%) | 0.44 | 0.44 | 0.30 | 0.24 | 0.31 |
| Current Ratio (X) | 1.49 | 1.57 | 1.71 | 1.30 | 1.20 |
| Quick Ratio (X) | 0.90 | 0.99 | 1.10 | 1.03 | 0.79 |
| Inventory Turnover Ratio (X) | 1.09 | 1.11 | 1.02 | 1.14 | 0.58 |
| Interest Coverage Ratio (X) | -1.35 | 1.60 | -10.43 | -0.01 | 0.46 |
| Interest Coverage Ratio (Post Tax) (X) | -10.52 | -9.48 | -29.74 | -2.31 | 0.21 |
| Enterprise Value (Cr.) | 2612.25 | 620.65 | 454.38 | 355.93 | 1682.86 |
| EV / Net Operating Revenue (X) | 4.67 | 1.11 | 0.98 | 0.53 | 2.69 |
| EV / EBITDA (X) | -497.57 | 108.22 | -9.81 | -122.86 | 19.43 |
| MarketCap / Net Operating Revenue (X) | 4.83 | 1.33 | 1.44 | 1.37 | 1.74 |
| Price / BV (X) | 3.24 | 0.90 | 0.80 | 1.07 | -4.34 |
| Price / Net Operating Revenue (X) | 4.83 | 1.33 | 1.44 | 1.37 | 1.74 |
| EarningsYield | 0.00 | 0.00 | -0.05 | 1.19 | -0.13 |
After reviewing the key financial ratios for Panacea Biotec Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -1.37. This value is below the healthy minimum of 5. It has decreased from -0.19 (Mar 24) to -1.37, marking a decrease of 1.18.
- For Diluted EPS (Rs.), as of Mar 25, the value is -1.37. This value is below the healthy minimum of 5. It has decreased from -0.19 (Mar 24) to -1.37, marking a decrease of 1.18.
- For Cash EPS (Rs.), as of Mar 25, the value is 4.26. This value is within the healthy range. It has decreased from 5.75 (Mar 24) to 4.26, marking a decrease of 1.49.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 136.18. It has increased from 133.94 (Mar 24) to 136.18, marking an increase of 2.24.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 136.18. It has increased from 133.94 (Mar 24) to 136.18, marking an increase of 2.24.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 91.21. It has decreased from 91.29 (Mar 24) to 91.21, marking a decrease of 0.08.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -0.85. This value is below the healthy minimum of 2. It has decreased from 0.93 (Mar 24) to -0.85, marking a decrease of 1.78.
- For PBIT / Share (Rs.), as of Mar 25, the value is -6.54. This value is below the healthy minimum of 0. It has decreased from -5.06 (Mar 24) to -6.54, marking a decrease of 1.48.
- For PBT / Share (Rs.), as of Mar 25, the value is -1.30. This value is below the healthy minimum of 0. It has decreased from 0.24 (Mar 24) to -1.30, marking a decrease of 1.54.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -1.42. This value is below the healthy minimum of 2. It has decreased from -0.24 (Mar 24) to -1.42, marking a decrease of 1.18.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -1.37. This value is below the healthy minimum of 2. It has decreased from -0.19 (Mar 24) to -1.37, marking a decrease of 1.18.
- For PBDIT Margin (%), as of Mar 25, the value is -0.93. This value is below the healthy minimum of 10. It has decreased from 1.02 (Mar 24) to -0.93, marking a decrease of 1.95.
- For PBIT Margin (%), as of Mar 25, the value is -7.16. This value is below the healthy minimum of 10. It has decreased from -5.53 (Mar 24) to -7.16, marking a decrease of 1.63.
- For PBT Margin (%), as of Mar 25, the value is -1.42. This value is below the healthy minimum of 10. It has decreased from 0.26 (Mar 24) to -1.42, marking a decrease of 1.68.
- For Net Profit Margin (%), as of Mar 25, the value is -1.55. This value is below the healthy minimum of 5. It has decreased from -0.26 (Mar 24) to -1.55, marking a decrease of 1.29.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -1.49. This value is below the healthy minimum of 8. It has decreased from -0.20 (Mar 24) to -1.49, marking a decrease of 1.29.
- For Return on Networth / Equity (%), as of Mar 25, the value is -1.00. This value is below the healthy minimum of 15. It has decreased from -0.14 (Mar 24) to -1.00, marking a decrease of 0.86.
- For Return on Capital Employeed (%), as of Mar 25, the value is -4.34. This value is below the healthy minimum of 10. It has decreased from -3.32 (Mar 24) to -4.34, marking a decrease of 1.02.
- For Return On Assets (%), as of Mar 25, the value is -0.64. This value is below the healthy minimum of 5. It has decreased from -0.09 (Mar 24) to -0.64, marking a decrease of 0.55.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.02. This value is within the healthy range. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.44. There is no change compared to the previous period (Mar 24) which recorded 0.44.
- For Current Ratio (X), as of Mar 25, the value is 1.49. This value is below the healthy minimum of 1.5. It has decreased from 1.57 (Mar 24) to 1.49, marking a decrease of 0.08.
- For Quick Ratio (X), as of Mar 25, the value is 0.90. This value is below the healthy minimum of 1. It has decreased from 0.99 (Mar 24) to 0.90, marking a decrease of 0.09.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.09. This value is below the healthy minimum of 4. It has decreased from 1.11 (Mar 24) to 1.09, marking a decrease of 0.02.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -1.35. This value is below the healthy minimum of 3. It has decreased from 1.60 (Mar 24) to -1.35, marking a decrease of 2.95.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -10.52. This value is below the healthy minimum of 3. It has decreased from -9.48 (Mar 24) to -10.52, marking a decrease of 1.04.
- For Enterprise Value (Cr.), as of Mar 25, the value is 2,612.25. It has increased from 620.65 (Mar 24) to 2,612.25, marking an increase of 1,991.60.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.67. This value exceeds the healthy maximum of 3. It has increased from 1.11 (Mar 24) to 4.67, marking an increase of 3.56.
- For EV / EBITDA (X), as of Mar 25, the value is -497.57. This value is below the healthy minimum of 5. It has decreased from 108.22 (Mar 24) to -497.57, marking a decrease of 605.79.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.83. This value exceeds the healthy maximum of 3. It has increased from 1.33 (Mar 24) to 4.83, marking an increase of 3.50.
- For Price / BV (X), as of Mar 25, the value is 3.24. This value exceeds the healthy maximum of 3. It has increased from 0.90 (Mar 24) to 3.24, marking an increase of 2.34.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.83. This value exceeds the healthy maximum of 3. It has increased from 1.33 (Mar 24) to 4.83, marking an increase of 3.50.
- For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Panacea Biotec Ltd:
- Net Profit Margin: -1.55%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -4.34% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -1% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -10.52
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.9
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 51.95)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.02
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -1.55%
About the Company
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Ambala-Chandigarh Highway, Lalru Punjab 140501 | companysec@panaceabiotec.com http://www.panaceabiotec.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Rajesh Jain | Chairman & Managing Director |
| Mr. Sandeep Jain | Joint Managing Director |
| Mr. Ankesh Jain | Whole Time Director |
| Mr. R L Narasimhan | Non Executive Director |
| Mr. N N Khamitkar | Non Executive Director |
| Mr. K M Lal | Non Executive Director |
| Mrs. Manjula Upadhyay | Non Executive Director |
| Mr. Bhupinder Singh | Non Executive Director |
| Mr. Mukul Gupta | Non Executive Director |
| Mr. Narotam Kumar Juneja | Non Executive Director |
Panacea Biotec Ltd. Share Price Update | |
|---|---|
| Share Price | Value |
| Today | ₹132.80 |
| Previous Day | ₹137.35 |
FAQ
What is the intrinsic value of Panacea Biotec Ltd?
Panacea Biotec Ltd's intrinsic value (as of 08 December 2025) is 81.30 which is 76.37% lower the current market price of 344.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 2,108 Cr. market cap, FY2025-2026 high/low of 582/281, reserves of ₹820 Cr, and liabilities of 1,254 Cr.
What is the Market Cap of Panacea Biotec Ltd?
The Market Cap of Panacea Biotec Ltd is 2,108 Cr..
What is the current Stock Price of Panacea Biotec Ltd as on 08 December 2025?
The current stock price of Panacea Biotec Ltd as on 08 December 2025 is 344.
What is the High / Low of Panacea Biotec Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Panacea Biotec Ltd stocks is 582/281.
What is the Stock P/E of Panacea Biotec Ltd?
The Stock P/E of Panacea Biotec Ltd is .
What is the Book Value of Panacea Biotec Ltd?
The Book Value of Panacea Biotec Ltd is 135.
What is the Dividend Yield of Panacea Biotec Ltd?
The Dividend Yield of Panacea Biotec Ltd is 0.00 %.
What is the ROCE of Panacea Biotec Ltd?
The ROCE of Panacea Biotec Ltd is 4.57 %.
What is the ROE of Panacea Biotec Ltd?
The ROE of Panacea Biotec Ltd is 4.92 %.
What is the Face Value of Panacea Biotec Ltd?
The Face Value of Panacea Biotec Ltd is 1.00.